Glenmark Launches BRUKINSA in India for B-Cell Cancers

  Published 1 year ago

Glenmark launches BRUKINSA, India's first BTK inhibitor for five B-cell cancers approved by DCGI with global trials and lower cardiac risks.

  • Treats CLL/SLL, WM, MCL, MZL, FL with proven efficacy and safety from ALPINE, ASPEN, SEQUOIA trials.
  • Addresses India's blood cancer burden with high response rates and flexible dosing for personalized care.
  • Shows 1.9% vs. 7.7% serious cardiac events vs. ibrutinib in relapsed/refractory CLL studies.

You might like these

Equippp Social Impact Tech Shares Rise

IRB Toll Revenue Rises 5% in June

V-Mart Q1 Profit Soars 361% YoY

Indian Stocks Steady Amid Trade Deal Hopes

Vishal Mega Mart Shares Drop 5.5% Amid Stake Sale

BSE Net Profit Doubles in Q1 FY26

India Needs $2.4 Trillion for Climate Cities

News that matters the most ⚡